Evaluation of Protein in the Urine in Patients Receiving Bevacizumab

North Texas Veterans Healthcare System106 enrolled

Overview

This is a clinical research study to look at the incidence of proteinuria (a condition in which urine contains an abnormal amount of protein) caused by shortened infusions (given into the vein over 10 or 15 minutes) of bevacizumab (a medication prescribed for colon, lung, or breast cancer). There are currently no published studies or clinical data looking at how safe shortened infusions of bevacizumab are in relationship to the side effect of proteinuria. We hypothesis that shortened infusions of bevacizumab will result in an increased risk for proteinuria compared to the standard infusions of this agent.

Study Type

OBSERVATIONAL

Enrollment

106

Conditions

Colon Cancer Rectal Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients must be 18 years older * Patients must be receiving his/her first dose of bevacizumab * Patients must sign an informed consent Exclusion Criteria: * Patients receiving \> 10 mg/kg doses of bevacizumab

Locations (3)

Outcomes

Primary Outcomes

To evaluate the effect of shortened infusions (0.5 mg/kg/min) of bevacizumab on the incidence of proteinuria.

Time frame: 3-6 months

Secondary Outcomes

To evaluate the time (number of days) to the incidence of proteinuria with shortened infusions of bevacizumab AND to evaluate the effect of controlled versus uncontrolled hypertension and the incidence of proteinuria.

Time frame: 3-6 months